215 related articles for article (PubMed ID: 29157298)
1. Impressive response to immunotherapy in a metastatic gastric cancer patient: could somatic copy number alterations help patient selection?
Dos Santos Fernandes G; da Motta Girardi D; Dib Batista Bugiato Faria L; Giacomini Bernardes JP; de Almeida Coudry R
J Immunother Cancer; 2017 Nov; 5(1):84. PubMed ID: 29157298
[TBL] [Abstract][Full Text] [Related]
2. Pembrolizumab for the treatment of gastric cancer.
Kamath SD; Kalyan A; Benson AB
Expert Rev Anticancer Ther; 2018 Dec; 18(12):1177-1187. PubMed ID: 30280940
[TBL] [Abstract][Full Text] [Related]
3. Evolution of checkpoint inhibitors for the treatment of metastatic gastric cancers: Current status and future perspectives.
Taieb J; Moehler M; Boku N; Ajani JA; Yañez Ruiz E; Ryu MH; Guenther S; Chand V; Bang YJ
Cancer Treat Rev; 2018 May; 66():104-113. PubMed ID: 29730461
[TBL] [Abstract][Full Text] [Related]
4. Immunotherapy for Gastric Cancer: A Focus on Immune Checkpoints.
Alsina M; Moehler M; Hierro C; Guardeño R; Tabernero J
Target Oncol; 2016 Aug; 11(4):469-77. PubMed ID: 26880697
[TBL] [Abstract][Full Text] [Related]
5. Translating gastric cancer genomics into targeted therapies.
Ang YL; Yong WP; Tan P
Crit Rev Oncol Hematol; 2016 Apr; 100():141-6. PubMed ID: 26947813
[TBL] [Abstract][Full Text] [Related]
6. Gastric cancer and the epoch of immunotherapy approaches.
Niccolai E; Taddei A; Prisco D; Amedei A
World J Gastroenterol; 2015 May; 21(19):5778-93. PubMed ID: 26019442
[TBL] [Abstract][Full Text] [Related]
7. Prognostic impact of gene copy number instability and tumor mutation burden in patients with resectable gastric cancer.
Cai L; Li L; Ren D; Song X; Mao B; Han B; Zhang H
Cancer Commun (Lond); 2020 Jan; 40(1):63-66. PubMed ID: 32141230
[No Abstract] [Full Text] [Related]
8. Immunotherapeutic Strategies for Gastric Carcinoma: A Review of Preclinical and Clinical Recent Development.
Abozeid M; Rosato A; Sommaggio R
Biomed Res Int; 2017; 2017():5791262. PubMed ID: 28781967
[TBL] [Abstract][Full Text] [Related]
9. Whole-Exome Sequencing of Metastatic Cancer and Biomarkers of Treatment Response.
Beltran H; Eng K; Mosquera JM; Sigaras A; Romanel A; Rennert H; Kossai M; Pauli C; Faltas B; Fontugne J; Park K; Banfelder J; Prandi D; Madhukar N; Zhang T; Padilla J; Greco N; McNary TJ; Herrscher E; Wilkes D; MacDonald TY; Xue H; Vacic V; Emde AK; Oschwald D; Tan AY; Chen Z; Collins C; Gleave ME; Wang Y; Chakravarty D; Schiffman M; Kim R; Campagne F; Robinson BD; Nanus DM; Tagawa ST; Xiang JZ; Smogorzewska A; Demichelis F; Rickman DS; Sboner A; Elemento O; Rubin MA
JAMA Oncol; 2015 Jul; 1(4):466-74. PubMed ID: 26181256
[TBL] [Abstract][Full Text] [Related]
10. Immunotherapy for oesophagogastric cancer.
Davidson M; Chau I
Expert Opin Biol Ther; 2016 Oct; 16(10):1197-207. PubMed ID: 27409159
[TBL] [Abstract][Full Text] [Related]
11. [Implications of TCGA Network Data on 2nd Generation Immunotherapy Concepts Based on PD-L1 and PD-1 Target Structures].
Peters I; Tezval H; Kramer MW; Wolters M; Grünwald V; Kuczyk MA; Serth J
Aktuelle Urol; 2015 Nov; 46(6):481-5. PubMed ID: 26560846
[TBL] [Abstract][Full Text] [Related]
12. The PD-1, PD-L1 expression and CD3+ T cell infiltration in relation to outcome in advanced gastric signet-ring cell carcinoma, representing a potential biomarker for immunotherapy.
Jin S; Xu B; Yu L; Fu Y; Wu H; Fan X; Wei J; Liu B
Oncotarget; 2017 Jun; 8(24):38850-38862. PubMed ID: 28418918
[TBL] [Abstract][Full Text] [Related]
13. Pan-cancer analysis of copy number changes in programmed death-ligand 1 (PD-L1, CD274) - associations with gene expression, mutational load, and survival.
Budczies J; Bockmayr M; Denkert C; Klauschen F; Gröschel S; Darb-Esfahani S; Pfarr N; Leichsenring J; Onozato ML; Lennerz JK; Dietel M; Fröhling S; Schirmacher P; Iafrate AJ; Weichert W; Stenzinger A
Genes Chromosomes Cancer; 2016 Aug; 55(8):626-39. PubMed ID: 27106868
[TBL] [Abstract][Full Text] [Related]
14. Immunotherapy for gastric cancers: emerging role and future perspectives.
Bonotto M; Garattini SK; Basile D; Ongaro E; Fanotto V; Cattaneo M; Cortiula F; Iacono D; Cardellino GG; Pella N; Fasola G; Antonuzzo L; Silvestris N; Aprile G
Expert Rev Clin Pharmacol; 2017 Jun; 10(6):609-619. PubMed ID: 28349740
[TBL] [Abstract][Full Text] [Related]
15. Immunotherapy for the treatment of breast cancer: checkpoint blockade, cancer vaccines, and future directions in combination immunotherapy.
McArthur HL; Page DB
Clin Adv Hematol Oncol; 2016 Nov; 14(11):922-933. PubMed ID: 27930644
[TBL] [Abstract][Full Text] [Related]
16. Genetics of Gastric Cancer.
Strand MS; Lockhart AC; Fields RC
Surg Clin North Am; 2017 Apr; 97(2):345-370. PubMed ID: 28325191
[TBL] [Abstract][Full Text] [Related]
17. Dendritic cell therapy in advanced gastric cancer: a promising new hope?
Tewari M; Sahai S; Mishra RR; Shukla SK; Shukla HS
Surg Oncol; 2012 Sep; 21(3):164-71. PubMed ID: 22521560
[TBL] [Abstract][Full Text] [Related]
18. Predictive biomarkers along gastric cancer pathogenetic pathways.
Panarese I; De Vita F; Ronchi A; Romano M; Alfano R; Di Martino N; Zito Marino F; Ferraraccio F; Franco R
Expert Rev Anticancer Ther; 2017 May; 17(5):417-425. PubMed ID: 28277834
[TBL] [Abstract][Full Text] [Related]
19. Systemic Treatments for Metastatic Renal Cell Carcinoma: 10-Year Experience of Immunotherapy and Targeted Therapy.
Kim SH; Park WS; Kim SH; Joung JY; Seo HK; Lee KH; Chung J
Cancer Res Treat; 2016 Jul; 48(3):1092-101. PubMed ID: 26875203
[TBL] [Abstract][Full Text] [Related]
20. Mismatch repair deficiency may affect clinical outcome through immune response activation in metastatic gastric cancer patients receiving first-line chemotherapy.
Giampieri R; Maccaroni E; Mandolesi A; Del Prete M; Andrikou K; Faloppi L; Bittoni A; Bianconi M; Scarpelli M; Bracci R; Scartozzi M; Cascinu S
Gastric Cancer; 2017 Jan; 20(1):156-163. PubMed ID: 26796888
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
